![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication August 24, 2004.
Revised October 26, 2004.
Accepted for publication November 2, 2004.
Efflux transporters such as P-glycoprotein (P-gp) and multidrug resistance associated proteins (Mrps) and their contributions to saquinavir (SQV) brain uptake were characterized. Cerebral flow rate was estimated from diazepam uptake and brain vascular volume was assessed using inulin. Mice brains were perfused with buffer containing SQV alone or co-perfused with different concentrations of GF120918, a specific P-gp inhibitor or MK571, a specific Mrp family inhibitor. Inulin, a nonabsorbable marker, was also co-perfused in all studies to assess if the inhibitors altered the physical integrity of the BBB. The estimated cerebral flow rate using diazepam was 250 ml·100g-1·min-1. The brain vascular volume, estimated using inulin, was almost constant (0.94 ± 0.03 ml·100g-1, n=12) during the perfusion study. SQV uptake kinetics were linear during the sampling period. Inclusion of 10 mM GF-120918 in the perfusate resulted in a more than 7-fold increase in the brain distributional volume (i.e., uptake) of SQV. Inclusion of 100mM MK571 in the perfusate increased SQV apparent brain uptake by more than 4.4-fold suggesting, for the first time, that Mrp transporters may play an important role in the brain uptake and retention of SQV. Neither GF-120918 nor MK571 altered the integrity of the BBB during the time course of the study. While the current results reaffirm that SQV is a P-gp substrate, this is the first report implicating the Mrp transporter family in the limited brain uptake and retention of SQV in vivo in mice.
Key words:
Brain, Mice, P-glycoprotein, Perfusion, Saquinavir, multidrug resistance associated proteins
This article has been cited by other articles:
|
|
 |
|
  M. Eilers, U. Roy, and D. Mondal MRP (ABCC) Transporters-Mediated Efflux of Anti-HIV Drugs, Saquinavir and Zidovudine, from Human Endothelial Cells Experimental Biology and Medicine, September 1, 2008; 233(9): 1149 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Chinn, J. M. Gow, M. M. Tse, S. L. Becker, and D. L. Kroetz Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein J. Antimicrob. Chemother., July 1, 2007; 60(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pan, N. Giri, and W. F. Elmquist Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine Drug Metab. Dispos., July 1, 2007; 35(7): 1165 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. von Hentig, A. Muller, C. Rottmann, T. Wolf, T. Lutz, S. Klauke, M. Kurowski, B. Oertel, B. Dauer, S. Harder, et al. Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1431 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dallas, D. S. Miller, and R. Bendayan Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev., June 1, 2006; 58(2): 140 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Park and P. J. Sinko THE BLOOD-BRAIN BARRIER SODIUM-DEPENDENT MULTIVITAMIN TRANSPORTER: A MOLECULAR FUNCTIONAL IN VITRO-IN SITU CORRELATION Drug Metab. Dispos., October 1, 2005; 33(10): 1547 - 1554. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
